Liu Yun-Long, Jing Li-Ling, Guo Qi-Sen
Department of Medical Oncology, Shandong Cancer Hospital and Institute, Jinan, China.
Asian Pac J Cancer Prev. 2013;14(1):351-4. doi: 10.7314/apjcp.2013.14.1.351.
To assess the practical utility of pleural fluid carbonic anhydrase XII (CAXII) quantification for differential diagnosis of effusions.
Fluid was collected prospectively from fifty patients presenting with lymphocytic pleural effusions for investigation and CAXII was quantified by ELISA.
Pleural fluid CAXII concentrations were significantly higher in lung cancer patients (n=30) than in tuberculous controls (n=20). The sensitivity and specificity of this biomarker were 60%and 75%, respectively. CAXII measurement was not inferior to cytological examination in the diagnosis and exclusion of pleural effusions from lung cancer patients (sensitivity 60% vs. 57%; specificity 75% vs. 100%; positive predictive value 77%; negative predictive value 54%). In patients with negative cytology, it offered a sensitivity of 54%.
Pleural fluid CAXII is elevated in pleural effusions from lung cancer patients. Measurement of CAXII may be used in the future as a valuable adjunct to cytology in the diagnostic assessment of patients with pleural effusions related to lung cancer, especially when cytological examination is inconclusive.
评估胸水碳酸酐酶XII（CAXII）定量检测在鉴别胸腔积液中的实际应用价值。
前瞻性收集50例淋巴细胞性胸腔积液患者的胸水进行研究，采用酶联免疫吸附测定法（ELISA）对CAXII进行定量检测。
肺癌患者（n = 30）胸水CAXII浓度显著高于结核对照组（n = 20）。该生物标志物的敏感性和特异性分别为60%和75%。在诊断和排除肺癌患者的胸腔积液方面，CAXII检测并不逊色于细胞学检查（敏感性60%对57%；特异性75%对100%；阳性预测值77%；阴性预测值54%）。在细胞学检查阴性的患者中，其敏感性为54%。
肺癌患者胸腔积液中CAXII升高。未来，CAXII检测可作为细胞学检查的重要辅助手段，用于诊断与肺癌相关的胸腔积液患者，尤其是在细胞学检查结果不明确时。
